Eli Lilly & Novo Nordisk Impose Universal 340B Claims Data Requirements — FQHCs Must Submit Data or Lose Pricing
For the first time, Eli Lilly (effective Feb 1, 2026) and Novo Nordisk (effective Apr 1, 2026) require all 340B covered entities — including FQHCs — to submit claims-level data for every in-house pharmacy and medical dispense, not just contract pharmacies. Lilly explicitly threatens to 'cancel 340B pricing' for non-compliant entities.
AHA has urged HRSA to intervene, calling compliance costs unprecedented. HRSA has not responded. FQHCs dispensing Lilly or Novo products must build new data submission workflows immediately.
Primary source
AHA / Healthcare DiveFQHC Talent. (2026, February 1). Eli Lilly & Novo Nordisk Impose Universal 340B Claims Data Requirements — FQHCs Must Submit Data or Lose Pricing. Primary source: AHA / Healthcare Dive. Retrieved June 12, 2026, from https://www.fqhctalent.com/intel/lilly-novo-340b-claims-data-mandate-2026
More in Risk & Compliance
Jul 5
Section 1557 Language Access Annual Notice Year 1 Anniversary — July 5, 2026 Compliance Window
Jun 9
FTCA CY2027 redeeming applications due June 26 — miss it and your FQHC has a malpractice-coverage gap
Jun 1
Two Compliance Signals for FQHCs: HRSA's FY2026 340B Manufacturer-Audit Results Go Live, and OCR's Ransomware Settlements Preview a Tougher HIPAA Security Rule
Jun 1
Eli Lilly Gives ~50 Covered Entities Five Days to Hand Over 340B Claims Data — or Lose Their Discounts